[Clinical features of the attentional deficit and hyperactivity disorder in epilepsy]
Viviana Venegas1,2, José María De Pablo1, Carmen Olbrich1
1Instituto de Neurocirugía Asenjo, Chile.
Insights
Epilepsy and attention deficit hyperactivity disorder (ADHD) frequently co-occur in children, often linked by cognitive deficits. Early suspicion, cognitive assessment, and multimodal treatment, including psychostimulants, are crucial for managing these complex conditions.
Area of Science:
- Pediatric Neurology
- Neurodevelopmental Disorders
Background:
- Epilepsy and attention deficit hyperactivity disorder (ADHD) are common pediatric conditions with complex associations.
- Psychiatric comorbidities frequently overlap between epilepsy and ADHD.
Purpose of the Study:
- To review the association between epilepsy and ADHD in children.
- To discuss risk factors, diagnostic approaches, and treatment strategies for co-occurring epilepsy and ADHD.
Main Methods:
- Literature review focusing on the relationship between epilepsy and ADHD.
- Analysis of epidemiological data, risk factors, and diagnostic criteria.
- Evaluation of treatment options and their impact on quality of life.
Main Results:
- ADHD and epilepsy affect both genders equally, with the inattentive subtype predominant.
- Cognitive deficits increase the risk of ADHD in epilepsy patients; network dysfunction is implicated.
- Psychostimulants are safe for treating ADHD in patients with or without epilepsy.
Conclusions:
- Diagnosis of ADHD in epilepsy patients should be based on clinical suspicion, cognitive assessments, and validated instruments.
- Multimodal treatment and specialized team support are recommended to improve outcomes.
- Untreated ADHD in epilepsy can lead to persistent negative academic, social, and emotional consequences.
Abstract:
Epilepsy and attention deficit and hyperactivity disorder (ADHD) are frequent conditions in pediatrics. Their association is frequent and complex, often sharing psychiatric comorbidity. Patients who present epilepsy and ADHD, show equal frequency in both genders, with the inattentive type, as predominant presentation. Cognitive deficit increases the risk of associating ADHD in patients with epilepsy. There is not enough evidence for other risk factors, however there is enough information that allows to ant icipate its presence in some types of epilepsy, with neuropsychological models that evidence the underlying network dysfunction. The relationship with frequency and seizure control, electroencephalographic alterations and antiepileptic drugs (AEDs) is also reviewed. Recommendations to reduce adverse effects of AEDs are described. The diagnosis must therefore be based on suspicion, through clinical instruments and assessments of cognitive functioning. Multimodal treatment is also recommended in patients with ADHD with and without epilepsy. Psych stimulants can be used safely. The quality of life of the patients and their families is affected, so it is advisable for them to be supported by a specialized team that could provide education, early assessment and therapy. If they are omitted, the consequences can be negative at school, social environment and emotional development, which could be relevant and become persistent.
More Related Videos
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...


